- Australia
- /
- Healthcare Services
- /
- ASX:IIQ
We're Not Very Worried About INOVIQ's (ASX:IIQ) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.
So should INOVIQ (ASX:IIQ) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.
How Long Is INOVIQ's Cash Runway?
A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. As at December 2024, INOVIQ had cash of AU$9.5m and no debt. Looking at the last year, the company burnt through AU$4.7m. Therefore, from December 2024 it had 2.0 years of cash runway. Arguably, that's a prudent and sensible length of runway to have. You can see how its cash balance has changed over time in the image below.
Check out our latest analysis for INOVIQ
How Well Is INOVIQ Growing?
INOVIQ reduced its cash burn by 17% during the last year, which points to some degree of discipline. Unfortunately, however, operating revenue declined by 17% during the period. In light of the data above, we're fairly sanguine about the business growth trajectory. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.
Can INOVIQ Raise More Cash Easily?
Even though it seems like INOVIQ is developing its business nicely, we still like to consider how easily it could raise more money to accelerate growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Commonly, a business will sell new shares in itself to raise cash and drive growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).
INOVIQ has a market capitalisation of AU$50m and burnt through AU$4.7m last year, which is 9.4% of the company's market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan.
How Risky Is INOVIQ's Cash Burn Situation?
Even though its falling revenue makes us a little nervous, we are compelled to mention that we thought INOVIQ's cash burn relative to its market cap was relatively promising. Cash burning companies are always on the riskier side of things, but after considering all of the factors discussed in this short piece, we're not too worried about its rate of cash burn. Taking an in-depth view of risks, we've identified 4 warning signs for INOVIQ that you should be aware of before investing.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts)
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ASX:IIQ
INOVIQ
Develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States.
Excellent balance sheet with moderate risk.
Similar Companies
Market Insights
Weekly Picks

Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market

AST SpaceMobile: The Boldest Direct-to-Cell Bet in Public Markets
Onto Innovation: The Advanced Packaging Chokepoint 51.3% undervalued intrinsic discount

Investment Analysis (May 2026)
Recently Updated Narratives

Making sense of 1.75 trillion IPO
SpaceX? Only Fast in - Fast out!

INDIAN OIL CORPORATION IS THE TITAN IN TRANSITION
Popular Narratives

Investment Analysis (May 2026)

Take-Two Interactive: The Calm Before the Storm NASDAQ: TTWO Last Price: $242.41 Date: May 15, 2026

Honeywell - The Demand-Side of the AI Infrastructure
Trending Discussion
